Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Spectrophotometric Assay from US Patent US20240124427: "HYDROXYHETEROCYCLOALKANE-CARBAMOYL DERIVATIVES"
Assay data:115 Active, 115 Activity ≤ 1 µM, 115 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Inhibitory Activity Assay from US Patent US20240109930: "TRIAZOLYL-METHYL SUBSTITUTED ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES"
Assay data:245 Active, 244 Activity ≤ 1 µM, 245 Tested
Evaluation of Kd Values from US Patent US20240059728: "NOVEL GALACTOSIDE INHIBITOR OF GALECTINS"
Assay data:6 Active, 3 Activity ≤ 1 nM, 6 Activity ≤ 1 µM, 6 Tested
Binding affinity to human Gal-1 assessed as decrease in Gal-1 levels by ELISA
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Binding affinity to Gal-1 (unknown origin) by SPR analysis
Binding affinity to Gal-1 (unknown origin) assessed as equilibrium constant by SPR analysis
Assay data:3 Tested
Binding affinity to Gal-1 (unknown origin) incubated for 30 mins by RP-HPLC analysis
Binding affinity to Gal-1 (unknown origin) by fluorescence spectroscopy
Assay data:6 Tested
Biological Assay from US Patent US20230348442: "GALECTIN-3 INHIBITING 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES"
Assay data:176 Active, 169 Activity ≤ 1 µM, 176 Tested
Evaluation of Compound Inhibitory Activity (IC50) from US Patent US20230295182: "SPIRO DERIVATIVES OF ALPHA-D-GALACTOPYRANOSIDES"
Assay data:115 Active, 112 Activity ≤ 1 µM, 115 Tested
Antagonist activity against human US7 patient-derived BCP-ALL cells assessed as inhibition of galectin-1-mediated cell-cell cluster formation at 500 uM incubated for 2 hrs by phase contrast microscopy
Antagonist activity against human TXL2 patient-derived BCP-ALL cells assessed as inhibition of galectin-1-mediated cell-cell cluster formation at 500 uM incubated for 2 hrs by phase contrast microscopy
Binding affinity to human galectin-3 by fluorescence polarization assay
Binding affinity to human galectin-1 by fluorescence polarization analysis
Antagonist activity against human US7 patient-derived BCP-ALL cells assessed as inhibition of galectin-3-mediated agglutination at 500 uM incubated for 2 hrs by phase contrast microscopy
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Antagonist activity against human TXL2 patient-derived BCP-ALL cells assessed as inhibition of galectin-3-mediated agglutination at 500 uM incubated for 2 hrs by phase contrast microscopy
Binding affinity to human galectin-3 using 2-(fluorescein-5/6-yl-carbonylamino)-ethyl 2-acetamido-2-deoxy-alpha-D-galactopyranosyl-(1-3)-[alpha-L-fucopyranosyl-(1-2)]-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranoside by fluorescence polarization analysis
Assay data:3 Active, 6 Tested
Binding affinity to human galectin-1 using 3,3'-dideoxy-3-[4-(fluorescein-5-yl-carbonylaminomethyl)-1H-1,2,3-triazol-1-y1]-3'.(3,5-dimethoxy-benzamido)-1,1'-sulfanediyl-di-beta-D-galactopyranoside as fluorescent probe by fluorescence polarization analysis
Assay data:5 Tested
Inhibition of Alexa-Fluor-647 conjugated galectin-3 binding to human osteoarthritic cartilage at 4 mM of sugar preincubated for 1 hr followed by incubation with tissue material for overnight by 2-colour fluorescence microsocopy
Assay data:2 Active, 2 Tested
Inhibition of Alexa-Fluor-488 conjugated galectin-1 binding to human osteoarthritic cartilage at 4 mM of sugar preincubated for 1 hr followed by incubation with tissue material for overnight by 2-colour fluorescence microsocopy
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on